🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMetabolic Health & DiabetesInsulin sensitivity vs insulin secretion — my results so far Page 2

Insulin sensitivity vs insulin secretion — my results so far

mel_PDX Fri, Aug 30, 2024 at 7:37 AM 15 replies 1,850 viewsPage 2 of 3
mike.trainer_LA
Senior Member
1,567
7,234
Apr 2024
Los Angeles, CA
Aug 31, 2024 at 12:05 AM#6
NurseKim_ATL said:
My labs after 6 months on glycaemic control: A1C 5.5%, fasting glucose 80 mg/dL, fasting insulin 9 uIU/mL.

Glycemic variability as the key metric for glycaemic control success: my coefficient of variation (CV) on CGM dropped from 35% to 18%. Target is <36%, with <30% being ideal.

Why this matters more than average glucose: large glucose swings cause oxidative stress, endothelial damage, and promote advanced glycation end-products (AGEs). A flat glucose line at 95 mg/dL is metabolically healthier than oscillating between 60 and 160, even if the average is the same.

Last edited: Aug 31, 2024 at 4:05 AM
23 18Dr.AddMedPHL, newstart_MO, mia_MS2 and 20 others
Reply Quote Save Share Report
lucas_SP_BR
Member
456
1,890
Jun 2024
São Paulo, BR
Aug 31, 2024 at 6:36 AM#7
mel_PDX said:
Fasting glucose improved within weeks and my HbA1c barely moved for three months, which I now understand and did not at the time.

Insulin sensitivity test (HOMA-IR) on glycaemic control — arguably the most important metabolic marker most people aren't tracking:

HOMA-IR = (fasting insulin × fasting glucose) ÷ 405

My numbers: Baseline HOMA-IR = 5.0 (insulin resistant) → Current = 1.2 (insulin sensitive)

Anything above 2.0 indicates insulin resistance. The goal is below 1.5. GLP-1 agonists address the root metabolic dysfunction, not just the symptoms. This is why they work so much better than calorie restriction alone.

Last edited: Aug 31, 2024 at 8:36 AM
22 17Dr.ObesityLA, NurseKim_ATL, paul_denver and 19 others
Reply Quote Save Share Report
lisa_labSD
Member
278
1,234
Oct 2024
San Diego, CA
Aug 31, 2024 at 1:07 PM#8
mike.trainer_LA said:
Glycemic variability as the key metric for glycaemic control success: my coefficient of variation (CV) on CGM dropped from 35% to 18%.

Fasting insulin is the lab my functional medicine doctor cares about most for glycaemic control: it's a much earlier marker of metabolic dysfunction than glucose or A1C.

My fasting insulin: 28 → 12 → 7 uIU/mL over 9 months. Target is <7. By the time your fasting glucose is elevated, your insulin has been elevated for YEARS trying to compensate.

Ask your doctor to include fasting insulin in your bloodwork panel. It's cheap (~$20) and incredibly informative.

21 16Dr.PulmRoch, maya_sedona, stefan_berlin and 18 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
raj_cambridge
Member
489
2,123
Jun 2024
Cambridge, MA
Aug 31, 2024 at 7:38 PM#9

A narrower follow-up, since the general answer is now clear:

Was that from a primary source or from a summary of one?

20 15PharmHunterJen, TomTeleRx, DoseLogDan and 17 others
Reply Quote Save Share Report
mel_PDX
Member
189
890
Dec 2024
Portland, OR
Sep 2, 2024 at 2:55 AM#10
lisa_labSD said:
Fasting insulin is the lab my functional medicine doctor cares about most for glycaemic control: it's a much earlier marker of metabolic dysfunction…

Complete metabolic panel trending on glycaemic control — sharing because comprehensive data helps everyone:

TestBaselineMonth 3Month 6Month 12
Glucose (fasting)113999383
Insulin (fasting)191396
HOMA-IR5.52.92.11.2
Uric Acid7.66.36.04.9

The insulin resistance improvement (HOMA-IR) is what my endo focuses on most. Going from 5.5 to near 1.0 is a metabolic transformation.

Last edited: Sep 2, 2024 at 8:55 AM
44 19RegAffairsDC, BiostatsBrad, PeptideSynthNJ and 41 others
Reply Quote Save Share Report

Similar Threads

SUSTAIN-6 to SELECT — the cardiovascular evidence timeline14 replies
GLP-1 and insulin resistance — HOMA-IR improvement data17 replies
Metabolic syndrome reversal criteria — how GLP-1 addresses all 55 replies
A1C target achievement rates — sema vs tirz comparison8 replies
SURPASS-CVOT: tirzepatide cardiovascular outcomes trial design3 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register